EUVIMED · CrossrefJournal
The Lancet Diabetes & Endocrinology
ISSN 2213-8587 · Elsevier BV
Latest articles
Trends in prevalence of type 2 diabetes and intermediate hyperglycaemia in Mauritius from 1987 to 2021 based on results from the oral glucose tolerance test: a repeated cross-sectional study
Presentation, management, and outcomes of ectopic Cushing syndrome: an international, multicentre, retrospective, cohort study
Correction to Lancet Diabetes Endocrinol 2026; 14: 149–56
Efficacy and safety of co-administered cagrilintide–semaglutide (CagriSema) 1·7 mg each and 1·0 mg each in adults with overweight or obesity (REDEFINE 9): a multicentre, randomised, double-blind within-dose-level, placebo-controlled, parallel-group, phase 3b trial
Diagnosing diabetes: the earlier the better
Getting personal with hormones: the ups and the downs
The right dose, not the highest dose: rethinking obesity pharmacotherapy
Effect of semaglutide on kidney outcomes in the SELECT, FLOW, and SOUL trials: a prespecified pooled analysis
Efficacy and safety of oral orforglipron in Japanese participants with obesity disease (ATTAIN-J): a double-blind, randomised, placebo-controlled, parallel-group, phase 3 trial
Clinical and metabolic subtypes of recent-onset adult type 1 diabetes: a prospective cohort study
The development of obesity pharmacotherapy: from early challenges and setbacks to recognition by WHO
Oral small-molecule GLP-1 receptor agonist for obesity in people from Japan
Who should prescribe obesity management medications? An IFSO position statement
Human versus analogue insulin for children and young adults with type 1 diabetes in low-resource settings (HumAn-1): a multicentre, open-label, randomised controlled trial
Nutritional, functional, and psychological considerations for incretin-based therapies in adults—an EASO, EFAD, and ECPO Consensus Statement
Insulin and health systems in global low-resource settings
An important new data source for obesity trends in England
Weight management in China: integrating mental health into routine obesity care
ADA Scientific Sessions 2026: a line crossed
Do weight loss and weight cycling present a clinically meaningful risk in older patients?
Soaring GLP-1 receptor agonist use
Energy drink ban: putting children's health first
Safety of biopsy in phaeochromocytoma and paraganglioma: an international, multicentre, retrospective cohort study
The risk of biopsy of phaeochromocytomas and paragangliomas
A quarter-century of progress: innovations in lipid medicine that transformed cardiovascular prevention
Obesity medications versus metabolic bariatric surgery: the debate goes on
Cagrilintide–semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study
Efficacy and safety of once-weekly cagrilintide–semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study
Cagrilintide–semaglutide: a new option for patients with type 2 diabetes
Diabetic foot ulcer prevention in Kuwait
EUVIMED